Bacteriophages against nosocomial infections
Scientists of the NGO "Microgen" create a highly effective complex preparation-bacteriophage
At the interregional scientific and practical conference "Ensuring epidemiological safety in surgical medical organizations, intensive care units and intensive care units" held in Perm, Perm scientists presented work on the creation of a new complex drug "Diphage" acting on Acinetobacter baumannii and Pseudomonas aeruginosa. It is these microorganisms that most often cause infections in patients of surgical hospitals, as well as intensive care units and intensive care units. Research work in this direction was carried out in the Perm branch of the NGO "Microgen" together with the staff of the St. Petersburg Medical Academy.
As the specialists of the Perm NGO Biomed noted, the development of "Diphage" is due to its special relevance. To date, Acinetobacter baumannii and Pseudomonas aeruginosa are not only the causative agents of a large number of nosocomial infections, but also exhibit high resistance to various classes of antibiotics.
During the development of the drug "Diphag", hospital strains of microorganisms Acinetobacter baumannii and Pseudomonas aeruginosa were selected at the bases of leading laboratories of medical organizations in Moscow, St. Petersburg, Perm, Yekaterinburg and Minsk. Extensive work has been carried out to study their biological properties in depth. In particular, several races of bacteriophages with high lytic activity against these pathogens have been obtained on the basis of NPO Biomed, the technology for obtaining the complex drug Diphage has been improved, its safety, specific activity, range of action and a number of other parameters necessary for further introduction into production have been studied, the press service of NPO Microgen reports.
Studies to evaluate the effectiveness of the drug conducted at clinical bases of medical institutions have shown that the strains of Acinetobacter baumannii and Pseudomonas aeruginosa circulating in intensive care units have high sensitivity to the experimental series of the drug "Diphag", at the same time they are exceptionally resistant to antibiotics. This means that this drug can find its application not only in the treatment of patients, but also as a means of preventive disinfection in the external environment of hospitals, preventing the development of infections and preventing their spread.
Currently, preclinical trials of the drug have been completed.
The conference participants noted that the use of bacteriophage preparations produced by the NGO "Microgen" is still one of the promising and priority areas for solving the issue of antibiotic resistance. Bacteriophages affect certain bacteria that are sensitive to them, causing the death of the latter and do not have a detrimental effect on the normal microflora. It has been established that the use of bacteriophages as monotherapy, in some cases, can provide a worthy alternative to antibiotics.
Recall that the Perm NGO "Biomed" has been producing bacteriophage preparations since 1995. Currently, the company has collected unique collections of microorganisms and phages, constantly improving the technological aspects of their production, including the release of new dosage forms.
NPO Microgen is the largest national manufacturer of immunobiological preparations, including bacteriophages. At the moment, the process of corporatization of the transfer of FSUE to Rostec Group, the managing holding of JSC National Immunobiological Company (JSC NIC), is underway.
Portal "Eternal youth" http://vechnayamolodost.ru
08.10.2015